Crinetics Pharmaceuticals Inc CRNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
-
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
-
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
-
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
-
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $52.77
- Day Range
- $52.73–53.59
- 52-Week Range
- $25.35–55.78
- Bid/Ask
- $53.20 / $85.08
- Market Cap
- $4.25 Bil
- Volume/Avg
- 394,997 / 633,728
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,642.47
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 210
- Website
- https://www.crinetics.com
Comparables
Valuation
|
Metric
|
CRNX
|
LLY
|
PTGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 79.49 | 16.56 |
Price/Book Value | 5.07 | 58.90 | 4.82 |
Price/Sales | 2,642.47 | 20.60 | 8.60 |
Price/Cash Flow | — | 79.87 | 13.77 |
Price/Earnings
CRNX
LLY
PTGX
Financial Strength
|
Metric
|
CRNX
|
LLY
|
PTGX
|
|---|---|---|---|
Quick Ratio | 15.96 | 0.61 | 13.60 |
Current Ratio | 16.09 | 1.11 | 13.73 |
Interest Coverage | — | 15.08 | — |
Quick Ratio
CRNX
LLY
PTGX
Profitability
|
Metric
|
CRNX
|
LLY
|
PTGX
|
|---|---|---|---|
Return on Assets (Normalized) | −29.20% | 13.15% | 44.65% |
Return on Equity (Normalized) | −33.39% | 69.16% | 49.43% |
Return on Invested Capital (Normalized) | −35.10% | 23.97% | 44.16% |
Return on Assets
CRNX
LLY
PTGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mmsmjgnph | Lgr | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zmfzhbvj | Lhjzfq | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lmjjthlj | Mpkqwhr | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yxkglcph | Gjbwdq | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Gzfklndl | Dbhj | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Chrmwjjj | Fkjr | $29.2 Bil | |||
| Moderna Inc
MRNA
| Lmmqpmq | Hqv | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Gzfcxysp | Khz | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hlfxfhnpy | Lqgsxc | $13.2 Bil | |||
| Incyte Corp
INCY
| Mjpthnv | Pfrxskv | $13.0 Bil |
United States